Cargando…

Benefit of intermediate-dose cytarabine-containing induction in molecular subgroups of acute myeloid leukemia

Detalles Bibliográficos
Autores principales:	Wei, Hui, Zhou, Chunlin, Lin, Dong, Liu, Bingcheng, Li, Yan, Zhao, Xingli, Wei, Shuning, Gong, Benfa, Liu, Kaiqi, Gong, Xiaoyuan, Liu, Yuntao, Zhang, Guangji, Chen, Jiayuan, Zhang, Junping, Jin, Jingjing, Qiu, Shaowei, Gu, Runxia, Wang, Ying, Mi, Yingchang, Wang, Jianxiang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Fondazione Ferrata Storti 2020
Materias:	Letters to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8094090/ https://www.ncbi.nlm.nih.gov/pubmed/33054134 http://dx.doi.org/10.3324/haematol.2020.267526

Ejemplares similares

Distinct genetic alteration profiles of acute myeloid leukemia between Caucasian and Eastern Asian population
por: Wei, Hui, et al.
Publicado: (2018)

Candidemia in Patients with Acute Leukemia: Analysis of 7 Years’ Experience at a Single Center in China
por: Gong, Xiaoyuan, et al.
Publicado: (2020)

The number of CD34+CD38+CD117+HLA-DR+CD13+CD33+ cells indicates post-chemotherapy hematopoietic recovery in patients with acute myeloid leukemia
por: Gu, Runxia, et al.
Publicado: (2017)

An analysis of 97 previously diagnosed de novo adult acute erythroid leukemia patients following the 2016 revision to World Health Organization classification
por: Qiu, Shaowei, et al.
Publicado: (2017)

The impact of venetoclax based regimens in the preemptive of measurable residual disease in acute myeloid leukemia
por: Fang, Qiuyun, et al.
Publicado: (2022)

High-Dose Cytarabine in Acute Myeloid Leukemia Treatment: A Systematic Review and Meta-Analysis
por: Li, Wei, et al.
Publicado: (2014)

Gene Deletions and Prognostic Values in B-Linage Acute Lymphoblastic Leukemia
por: Fang, Qiuyun, et al.
Publicado: (2021)

Efficacy of combination of venetoclax with azacitidine or chemotherapy in refractory/relapse acute leukemias of ambiguous lineage, not otherwise specified
por: Liu, Kaiqi, et al.
Publicado: (2021)

Treatment of STAT5b-RARA positive acute promyelocytic leukemia by Venetoclax combining with homoharringtonine, cytarabine: A case report and literature review
por: Zhang, Guangji, et al.
Publicado: (2022)

Chimeric antigen receptor-modified T-cell therapy for bone marrow and skin relapse Philadelphia chromosome-like acute lymphoblastic leukemia: A case report
por: Yang, Mianzeng, et al.
Publicado: (2020)

The clinical characteristics and prognosis in adult Ph negative acute lymphoblastic leukemia with TP53 aberrations
por: Fang, Qiuyun, et al.
Publicado: (2022)

Efficacy and safety of CD19 CAR T constructed with a new anti-CD19 chimeric antigen receptor in relapsed or refractory acute lymphoblastic leukemia
por: Gu, Runxia, et al.
Publicado: (2020)

Heterogeneity analysis of the CEBPAdm AML based on bZIP region mutations
por: Hui, Yan, et al.
Publicado: (2023)

Reduced ABO blood group antibody titers in patients after CD19 CAR-T cell therapy
por: Li, Qiang, et al.
Publicado: (2022)

Intermediate-dose cytarabine is an effective therapy for adults with non-Langerhans cell histiocytosis
por: Liu, Ting, et al.
Publicado: (2022)

Spectrum of somatic mutations detected by targeted next-generation sequencing and their prognostic significance in adult patients with acute lymphoblastic leukemia
por: Feng, Juan, et al.
Publicado: (2017)

The prognostic benefit from intermediate-dose cytarabine as consolidation therapy varies by cytogenetic subtype in t(8;21) acute myeloid leukemia: a retrospective cohort study
por: Chen, Guofeng, et al.
Publicado: (2022)

P507: SALVAGE THERAPY WITH VENETOCLAX IN COMBINATION WITH AZACITIDINE, HOMOHARRINGTONINE AND CYTARABINE IN PATIENTS WITH RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA
por: Yuan, Linyu, et al.
Publicado: (2023)

Mature plasmacytoid dendritic cells associated with acute myeloid leukemia show similar genetic mutations and expression profiles to leukemia cells
por: Gong, Xiaoyuan, et al.
Publicado: (2022)

Venetoclax combined with daunorubicin and cytarabine (2 + 6) as induction treatment in adults with newly diagnosed acute myeloid leukemia: a phase 2, multicenter, single-arm trial
por: Suo, Xiaohui, et al.
Publicado: (2023)

Retrospective Comparison of Fludarabine in Combination With Intermediate-Dose Cytarabine Versus High-Dose Cytarabine As Consolidation Therapies for Acute Myeloid Leukemia
por: Zhang, Wenjun, et al.
Publicado: (2014)

Effects of genetic polymorphisms on methotrexate levels and toxicity in Chinese patients with acute lymphoblastic leukemia
por: Hao, Qishan, et al.
Publicado: (2022)

Rational design of a new cytarabine-based prodrug for highly efficient oral delivery of cytarabine
por: Zhang, Jing, et al.
Publicado: (2018)

Intermediate dose cytarabine improves survival and relapse-free rate compared with standard-dose cytarabine as post-remission treatment for acute myeloid leukemia: A retrospection study
por: Ye, Li, et al.
Publicado: (2021)

Meta-Analysis of Randomised Clinical Trials Comparing Idarubicin + Cytarabine with Daunorubicin + Cytarabine as the Induction Chemotherapy in Patients with Newly Diagnosed Acute Myeloid Leukaemia
por: Wang, Jing, et al.
Publicado: (2013)

Auer rods in mixed phenotype acute leukemia, T/myeloid: A report of three cases
por: Li, Yan, et al.
Publicado: (2021)

Cytarabine-Induced Encephalitis
por: Lenfant, Christine, et al.
Publicado: (2021)

Intermediate-dose cytarabine or standard-dose cytarabine plus single-dose anthracycline as post-remission therapy in older patients with acute myeloid leukemia: impact on health care resource consumption and outcomes
por: Galtier, Jean, et al.
Publicado: (2021)

Multivariate and subgroup analyses of a randomized, multinational, phase 3 trial of decitabine vs treatment choice of supportive care or cytarabine in older patients with newly diagnosed acute myeloid leukemia and poor- or intermediate-risk cytogenetics
por: Mayer, Jiří, et al.
Publicado: (2014)

Curcumin sensitizes response to cytarabine in acute myeloid leukemia by regulating intestinal microbiota
por: Liu, Junmin, et al.
Publicado: (2022)

Phase I study of alvocidib plus cytarabine/mitoxantrone or cytarabine/daunorubicin for acute myeloid leukemia in Japan
por: Ikezoe, Takayuki, et al.
Publicado: (2022)

Patients with AML-MRC benefit from decitabine in combination with low-dose G-CSF, cytarabine and aclarubicin: A single center cohort study
por: Liu, Jing, et al.
Publicado: (2022)

A novel cytarabine crystalline lipid prodrug: Hexadecyloxypropyl cytarabine 3′,5′-cyclic monophosphate for proliferative vitreoretinopathy
por: Kim, Jae Suk, et al.
Publicado: (2012)

Bioinformatic analysis of the effects and mechanisms of decitabine and cytarabine on acute myeloid leukemia
por: Zhou, Shiyong, et al.
Publicado: (2017)

Impact of induction chemotherapy with intermediate-dosed cytarabine and subsequent allogeneic stem cell transplantation on the outcome of high-risk acute myeloid leukemia
por: Fleischmann, Maximilian, et al.
Publicado: (2021)

Standard-Intensity Induction and Intermediate/High-Dose Cytarabine Consolidation Can Improve Survival for Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia: A Retrospective Cohort Study
por: Wang, Li, et al.
Publicado: (2022)

Role of cytarabine in paediatric acute promyelocytic leukemia treated with the combination of all-trans retinoic acid and arsenic trioxide: a randomized controlled trial
por: Zhang, Li, et al.
Publicado: (2018)

Comparison of multi-omics results between patients with acute myeloid leukemia with long-term survival and healthy controls
por: Song, Yang, et al.
Publicado: (2022)

Enhanced sensitivity to glucocorticoids in cytarabine-resistant AML
por: Malani, D, et al.
Publicado: (2017)

Cytarabine-Induced Bradycardia: A Case Report
por: Albsheer, Khalid, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_l9a58rlhvvb91epj906as7sd3e